Bile Acids in Liver Diseases

List of principal authors. Preface. Section I: Bile acid synthesis. 1. Species differences in bile acid metabolism; A.F. Hofmann, et al. 2. Role of alternative pathways of bile acid biosynthesis in liver disease; J. Sjövall. 3. Regulation of bile acid synthesis; Z.R. Vlahcevic, et al. Section II: Bile acid transport. 4. Hepatocellular basolateral bile acid uptake proteins; B. Hagenbusch, et al. 5. Transcellular bile acid transport; J.M. Crawford. 6. Bile acid transport across the canalicular membrane; D. Keppler, et al. 7. The hepatic Na+ taurocholate cotransporter is downregulated in experimental models of cholestasis; C. Gartung, J.L. Boyer. Section III: New concepts of bile acid-induced hepatotoxicity and bile secretion. 8. Effect of bile salts on biomembranes; S. Güldütuna, et al. Apoptosis - an alternative mechanism of bile salt hepatotoxicity; T. Patel, et al. 10. Bile acids and hepatocellular signalling; U. Beuers, et al. 11. Hepatobiliary cholesterol secretion and the function of mdr2 P-glycoprotein; R.P.J. Oude Elferink, et al. Section IV: Bile secretory function of liver and bile duct cells. 12. Vesicle targeting to the canalicular domain regulates bile acid transport and bile secretory function in the liver; J.L. Boyer, et al. 13. Effects of bile acids on bile duct epithelial cells; M. Strazzabosco, et al. 14. Increased biliary secretion of phospholipids in primary sclerosing cholangitis: another mechanism of action of ursodeoxycholic acid? A. Stiehl, et al. 15. Bile acid transport systems as pharmaceutical targets: bile acid-derived HMG-CoA reductase inhibitors; W. Kramer, et al. Section V: Ursodeoxycholic acid treatment in cholestatic liver diseases. 16. Long-term experience with ursodeoxycholic acid for patients with biliary cirrhosis and primary sclerosing cholangitis. 17. State of the Art Lecture: Ursodeoxycholic acid in cholestatic liver diseases &endash; clinical efficiency and putative mechanism of action; R. Poupon. Index.